The clinical path to deliver encapsulated phages and lysins.
The clinical path to deliver encapsulated phages and lysins.
复制标题
DOI：
10.1093/femsre/fuab019
复制
发表时间：
2021-03
影响因子：
11.3
通讯作者：
A. M. Pinto;M. D. Silva;L. Pastrana;M. Bañobre‐López;S. Sillankorva
中科院分区：
文献类型：
--
作者：
A. M. Pinto;M. D. Silva;L. Pastrana;M. Bañobre‐López;S. Sillankorva
全球多重耐药病原体的出现正在塑造当前关于使用抗生素疗法的教条。许多细菌已经进化出对传统抗生素疗法的抗药性，给患者带来了健康和经济负担。对替代和补充治疗方法的探索加强并复兴了噬菌体疗法。近几十年来，噬菌体基因组编码的溶素的外源使用已显示出令人鼓舞的有效性。这两种抗菌剂可减少细菌数量；然而，许多障碍挑战了它们在感染部位的及时递送。封装在递送载体中提供了具有受控化合物递送的靶向治疗，超越了可以灭活和消除它们的化学、物理和免疫屏障。本综述探讨了噬菌体和溶素目前用于解决呼吸、消化和外皮系统细菌感染的用途。我们还强调了它们在这三个系统中面临的不同挑战，并讨论了更广泛地使用运载工具的进展。
The global emergence of multidrug-resistant pathogens is shaping the current dogma regarding the use of antibiotherapy. Many bacteria have evolved to become resistant to conventional antibiotherapy, representing a health and economic burden for those afflicted. The search for alternative and complementary therapeutic approaches has intensified and revived phage therapy. In recent decades, the exogenous use of lysins, encoded in phage genomes, has shown encouraging effectiveness. These two antimicrobial agents reduce bacterial populations; however, many barriers challenge their prompt delivery at the infection site. Encapsulation in delivery vehicles provides targeted therapy with a controlled compound delivery, surpassing chemical, physical and immunological barriers that can inactivate and eliminate them. This review explores phages and lysins' current use to resolve bacterial infections in the respiratory, digestive, and integumentary systems. We also highlight the different challenges they face in each of the three systems and discuss the advances towards a more expansive use of delivery vehicles.